Introduction 52
Pulmonary infection represents a major cause of morbidity and mortality among cystic 53 fibrosis (CF) patients (1) . These patients are therefore regularly exposed to antibiotics for the 54 treatment of infectious exacerbations as well as for the prevention of chronic colonization. 55
Pseudomonas aeruginosa is one of the most prevalent bacterial species, especially in the 56 adult population (2). It is well known for its genetic plasticity and capacity to accumulate 57 resistance mechanisms, including acquisition of foreign genetic material (3). The 58 percentage of patients colonized by P. aeruginosa has decreased in recent years (2) but, 59
with improved life expectancy, the absolute number of colonized patients has increased. It 60 has also been proposed that multidrug resistant (MDR) strains are more frequent in older 61 patients, primarily due to cumulative exposure to antibiotics (2). A further reason for the 62 spread of antibiotic resistance in CF patients is the dissemination of MDR clones. The 63
Liverpool Epidemic Strain (LES), first described in 1996 (4), has proven particularly 64 successful for acquiring resistance mechanisms over the years (5,6) and for spreading from 65 the UK to other countries such as Canada, Spain and Australia (7) . 66
In this study, we compared the antimicrobial susceptibility of P. aeruginosa isolated from CF 67 patients in the United Kingdom (UK), where the MDR LES clone is known to be highly 68 prevalent (5), with an equivalent number of strains collected in Germany and Belgium, where 69 no specific survey has been published over the last years. We determined the presence of 70 co-resistance to unrelated antibiotic classes and its possible association with MDR clones. 71
We found that resistance was high in the three countries, but not related to the dissemination 72 of a specific MDR clone in Germany or Belgium. Carbapenems, tobramycin, and colistin 73
Materials and methods 77 78

Bacterial isolates 79
A total of 153 clinical P. aeruginosa isolates were selected at random among those collected 80 between 2006 and 2012 in 3 CF centers from Belgium (Hôpital des enfants malades Reine 81 Fabiola/Erasme Hospital, n = 44); Germany (University Hospital of Münster, n = 51) and UK 82 (Queen's University of Belfast, n = 58) during routine visits. The details on the collection are 83 shown in Table 1 . When successive strains were collected from a single patient, only those 84 collected at the first occasion were considered. Nevertheless, more than one isolate were 85 analyzed for some patients based on differences in their phenotypic appearance (see Figure  86 S1 in supplemental material). 87 88 Antibiotics 89
The following antibiotics were obtained as microbiological standards ( bla SHV , bla CTX-M (groups 1, 2 and 9), bla VIM , bla IMP , bla KPC , and bla NDM gene families were 116 detected by real-time multiplex PCR, using group-specific primers ([11-13] and references 117 cited therein). Other genes encoding OXA (1, 2, 9, 10, 18, 20, 23, 24, 30, 48, 58, 198) , BEL (1 to 118 3), PER (1 to 5, and 7), GES (1 to 18), and VEB (1 to 7) enzymes were also detected by 119 multiplex PCR. 120 121
Molecular typing 122
All MDR isolates in the collection showing co-resistance to penicillins and/or cephalosporins 123 and two other classes (n=56) were characterized by Pulsed-Field Gel Electrophoresis 124 (PFGE) analysis (14). In addition, 42 pairs of isolates collected simultaneously and in the 125 same sample from 21 patients (see Figure S1 ) but differing in their susceptibility profile to at 126 least one class of antibiotics were also genotyped by PFGE to determine their genetic 127 relatedness. The pulsotype classification criteria designated a pulsotype by one or two 128 letters including patterns showing zero to six DNA fragments differences (14). An epidemic 129
Results 137 Table 2 shows the MIC distribution for 9 antipseudomonal drugs against 153 isolates 139 collected from 120 CF patients originating from three different countries over the 2006-2012 140 period, together with the percentage susceptible and resistant based on both EUCAST and 141 CLSI interpretive criteria. The corresponding MIC cumulative distributions are illustrated in 142 Figure S2 . Resistance was high in this collection. Using the EUCAST or the CLSI "R" 143 breakpoints, respectively, full resistant isolates were ≥71% or ≥54% for penicillins (ticarcillin, 144 piperacillin, piperacillin-tazobactam), 69% or 59% for ceftazidime, 61% or 46% for amikacin, 145 56% or 27% for ciprofloxacin, ≥20% for carbapenems, and 28 or 16% for tobramycin. Full 146 resistance to colistin was noted for only 8% of the isolates. Strains resistant to ceftazidime 147 and meropenem were screened for the expression of frequent ESBLs, metallo β-148 lactamases, and carbapenemases, which returned negative results. 149 150
MIC distributions 138
Cross-or co-resistance 151
Cross-or co-resistance was examined among pairs of antibiotics. Cross-resistance is 152 defined as a single resistance mechanism that confers resistance to antimicrobial molecules 153 with a similar mechanism(s) of action. It thus describes resistance to an entire class of 154 antibiotics, or to different classes of agents with overlapping drug targets, or to different 155 classes of antibiotics that are substrates for the same broad-spectrum efflux system. Co-156 resistance rather refers to the presence of different mechanisms of resistance in the same 157 bacterial isolate, and is thus necessarily confers resistance to unrelated antibiotic classes 158 (17). Ninety-four strains were considered as MDR according the ECDC (10). The right upper 159 part of Table 3 shows the percentage of strains showing cross-or co-resistance to pairs of 160 antibiotics according to EUCAST criteria. About 2/3 of the strains were resistant to both 161 penicillins and ceftazidime and more than 40%, to penicillins and ceftazidime together with meropenem, and colistin was lower than 28%, 20% and 8%, respectively. Of note, only 4 164 strains in the whole collection were co-resistant to meropenem, tobramycin, and colistin 165 ( Figure S3 ). 166
The left lower part of Table 3 shows the correlation coefficient between the individual MIC for 167 each pair of antibiotics, with the corresponding multivariate analysis presented in details as 168
supplementary Figure S4 . The highest degrees of correlation (> 0.75) between individual 169
MICs were observed for ticarcillin vs. ceftazidime, piperacillin vs. piperacillin-tazobactam, 170 ceftazidime vs. piperacillin-(tazobactam), imipenem vs. meropenem, and amikacin vs. 171
tobramycin, suggesting common mechanisms of resistance between these pairs of 172
antibiotics. Yet, differences in the intrinsic potency were nevertheless observed between 173 these pairs of drugs throughout the collection; they are illustrated in Figure S4 and 174 associated Table B : tazobactam reduced the MIC of piperacillin by a factor of 1.5 dilution, 175 while ceftazidime MICs were 0.5 and 1 dilution lower than those of ticarcillin and piperacillin 176 respectively, and similar to those of piperacillin-tazobactam. Meropenem MICs were 1 177 dilution lower than those of imipenem, and tobramycin MICs were 3 dilutions lower than 178 those of amikacin. 179 180
Typing of MDR isolates 181
Among the 94 MDR isolates, most were resistant to penicillins and/or cephalosporins. Only 182 those showing resistance to at least 2 other classes (n = 56) were characterized by PFGE 183 analysis. A high genetic diversity was observed, with 19 sporadic pulsotypes and 9 epidemic 184 pulsotypes (Table 4 ). With the exception of pulsotype YY recovered for 1 or 2 isolates in the 185 three countries, each epidemic pulsotype remained localized in a single country. The CA 186 displaying different susceptibility profiles (Table S1 ). In twelve patients, the pair of 191 P. aeruginosa isolates had the same pulsotype, while the 9 other patients had isolates with 192 different pulsotypes. In this study, we examined antibiotic susceptibility of a collection of P. aeruginosa isolated 207 from CF patients in three Northern European countries during routine examination, which 208 provides a broader view than the majority of previous surveys that have focused on a single 209 country (18-20) or a single center (21-23). A key observation is that resistance rates were 210 high in this population, confirming previous studies with CF patients (2), and notably 211 A.9.much higher than that which has been reported for isolates collected in Northern 212
European from intensive care units (24-26). Resistance rates were also higher than those 213 previously reported for strains from CF patients in a German survey from the University of 214 resistance has previously been described in the LES clone (5) but the underlying 245 mechanism(s) have not been investigated to date. For aminoglycosides, the higher potency 246 of tobramycin over amikacin in our collection also reflects what is observed in MIC 247 distributions of wild-type strains assembled by EUCAST (29). Tobramycin has been 248 described as a poorer substrate than amikacin for the efflux pump MexXY-OprM considered 249 as responsible for natural and adaptative resistance to aminoglycosides in P. aeruginosa 250 (36,37). 251
Considering our findings from a clinical perspective, a high degree of cross-resistance was 252 observed between penicillins and ceftazidime, which was expected. However, a high degree 253 of co-resistance was also apparent between these antibiotics and both ciprofloxacin and 254 amikacin, resulting in 60 % of the isolates being categorized as multidrug resistant. In 255 contrast, meropenem, and colistin, and to a lesser extent, tobramycin, were active against a 256 large fraction of the isolates with few strains co-resistant to these three antibiotics. We also noticed an important genetic diversity among multi-resistant isolates collected in 263
Belgium and Germany while those collected in the UK belong in majority to the Liverpool 264
Epidemic Strain (LES) clone. Global studies of P. aeruginosa population structure concluded 265 that CF isolates present a high genetic diversity but nevertheless belong to a 'core lineage' 266 ubiquitous in the natural environment (43), which is highly suggestive of a direct colonization 267 of the patients from the environment. However, a series of epidemic clones have been 268 described (7) among which the LES (4) representing 18 of the 24 MDR isolates collected in 269 the UK in our study, and the ST17 (7), which differs by only 1 nucleotide from the ST958 270 found in the three countries investigated here. The new ST2254 we described was distinct 271 from ST146 (LES clone, 5 alleles difference) and ST958 or ST17 (6 alleles difference). 272
273
We observed that a single patient can be colonized by different strains and, conversely, that 274 clonally-related strains isolated at the same time from a single patient can harbor diverse 275 susceptibility profiles. This could be a consequence of the previously described phenotypic 276 variability among isolates with the same colony morphotype and being part of a single clonal 277 lineage (44,45), as well as of recombination occurring in vivo and generating phenotypic and 278 genetic diversification (46, 47) . 279
280
Although limited, differences in resistance rates between Belgium and the other two other 281 countries are raising questions about segmentation of clone distribution. For strains collected 282 in the UK, higher resistance is clearly related to the high prevalence of the LES clone, which 283 has been described as exhibiting a large proportion of MDR isolates (5). Of interest, we 284 observed different resistance profiles within this clone, which is coherent with the previously 285 described phenotypic variability among LES isolates (6). The ST958 represented in the 286 three countries is also found among the MDR clonal complexes clones than in the two other countries. We cannot exclude differences in therapeutic 289 management of patients among these three centers that may influence resistance selection 290 (48) but this specific aspect was not within the scope of our study. 291
292
Resistance rates were not higher in the older population than in children/young adults. The 293 interpretation of these data need to be cautious because (a) we did not follow the evolution 294 of susceptibility over time in single patients and (b) we do not know the age of first 295 colonization for each patient. With this limitation in mind, the fact that MDR isolates could be 296 found in young people and susceptible isolates in adults may suggest that resistance 297 depends on the initial susceptibility of the infecting strain. A link between emergence of 298 resistance and early antibiotic use in CF patients is still controversial, even though 299 underlined in the last report of the Cystic Fibrosis Foundation (2). A recent study in Australia 300 showed that multiresistance in children is correlated with duration of intravenous antibiotic 301 treatment, which was not the case for adults (18). A correlation with antibiotic usage 302 irrespective of patient's age (49) or with time after colonization (6) has also been proposed. 303
In contrast, other studies following the evolution of antibiotic susceptibility in successive 304 isogenic isolates from a single patient suggest either that resistance can occur sporadically 305 (50) or without correlation with the time of isolation (51). In these cases, the presence of 306 mutator variants seems to predetermine the risk of developing resistance over time (6) . 307
308
Our study has a number of limitations, primarily linked to the fact that samples collected 309 during periodic routine examinations may not correspond to the first isolates of 310 P. aeruginosa infections in these patients. Moreover, as we did not have the history of 311 antibiotic use in these patients, we could not determine if there was a potential link between The numbers below the diagonal correspond to the correlation coefficient between individual MIC values for each pairs of antibiotics. Values 547 higher than 0.75 are highlighted in bold characters. See Table 2 for abbreviations of antibiotics and Figure S4 for the details of this analysis. 548 549 
Percentage of cross-or co-
